118 Avenue , 14315
Suite 140
Edmonton, AB T5L 4S6
Canada
250 744 2487
https://www.auriniapharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 300
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Peter S. Greenleaf M.B.A. | President, CEO & Director | 1,34M | N/D | 1970 |
Mr. Joseph M. Miller CPA | Chief Financial Officer | 791,92k | N/D | 1974 |
Mr. Matthew Maxwell Donley M.B.A. | Executive Vice President of Operations & Strategy | 811,82k | N/D | 1969 |
Mr. Stephen P. Robertson | Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer | 739,68k | N/D | 1982 |
Dr. Volker Knappertz D.Sc., M.D. | Executive Vice President of Research & Development | 742,85k | N/D | 1965 |
Andrea Levin Christopher | Head of the Corporate Communications & Investor Relations | N/D | N/D | N/D |
Mr. Fran Lynch | Vice President of Sales | N/D | N/D | N/D |
Mr. Michael R. Martin | Chief Business Officer | 350,57k | N/D | 1972 |
Ms. Sue Evans | Senior Vice President of Global Regulatory Affairs | N/D | N/D | N/D |
Mr. Scott Habig | Chief Commercial Officer | N/D | N/D | 1960 |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
L'ISS Governance QualityScore di Aurinia Pharmaceuticals Inc. al 29 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 5; diritti degli azionisti: 2; retribuzione: 10.